Celgene Co. (CELG) Holdings Cut by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lowered its stake in shares of Celgene Co. (NASDAQ:CELG) by 95.8% in the first quarter, HoldingsChannel.com reports. The firm owned 310 shares of the biopharmaceutical company’s stock after selling 7,030 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Celgene were worth $29,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in CELG. Janney Capital Management LLC boosted its position in shares of Celgene by 2.9% in the fourth quarter. Janney Capital Management LLC now owns 4,219 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 120 shares during the period. Iberiabank Corp boosted its position in shares of Celgene by 1.0% in the first quarter. Iberiabank Corp now owns 12,019 shares of the biopharmaceutical company’s stock valued at $1,134,000 after acquiring an additional 121 shares during the period. Pitcairn Co. boosted its position in shares of Celgene by 3.0% in the fourth quarter. Pitcairn Co. now owns 4,289 shares of the biopharmaceutical company’s stock valued at $275,000 after acquiring an additional 124 shares during the period. Winthrop Advisory Group LLC boosted its position in shares of Celgene by 4.1% in the fourth quarter. Winthrop Advisory Group LLC now owns 3,171 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 125 shares during the period. Finally, Asset Dedication LLC raised its stake in shares of Celgene by 35.5% in the first quarter. Asset Dedication LLC now owns 477 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 125 shares in the last quarter. 71.71% of the stock is owned by hedge funds and other institutional investors.

Celgene stock opened at $94.15 on Wednesday. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.78 and a quick ratio of 2.66. Celgene Co. has a 52-week low of $58.59 and a 52-week high of $97.07. The firm has a market cap of $66.33 billion, a price-to-earnings ratio of 11.24, a P/E/G ratio of 0.43 and a beta of 1.68.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.45 by $0.10. Celgene had a return on equity of 106.69% and a net margin of 30.10%. The firm had revenue of $4.03 billion during the quarter, compared to analyst estimates of $4.01 billion. During the same period in the prior year, the company posted $2.05 earnings per share. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. Equities analysts anticipate that Celgene Co. will post 9.85 EPS for the current fiscal year.

A number of research analysts recently commented on the company. ValuEngine upgraded Celgene from a “sell” rating to a “hold” rating in a research note on Saturday, May 4th. Barclays lowered Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price for the company. in a research note on Friday, May 3rd. BidaskClub upgraded Celgene from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Mizuho set a $103.00 target price on Celgene and gave the company a “buy” rating in a research note on Friday, April 5th. Finally, Cantor Fitzgerald lowered Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 target price for the company. in a research note on Friday, April 5th. Twenty equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Celgene has a consensus rating of “Hold” and an average target price of $95.96.

COPYRIGHT VIOLATION NOTICE: “Celgene Co. (CELG) Holdings Cut by Oppenheimer Asset Management Inc.” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/15/celgene-co-celg-holdings-cut-by-oppenheimer-asset-management-inc.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: What is Call Option Volume?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.